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Abstract Cytochrome c release from mitochondria is central to
apoptosis, but the events leading up to it are disputed. The
mitochondrial membrane potential has been reported to decrease,
increase or remain unchanged during cytochrome c release. We
measured mitochondrial membrane potential in Jurkat cells
undergoing apoptosis by the uptake of the radiolabelled lipophilic
cation TPMP, enabling small changes in potential to be
determined. The ATP/ADP ratio, mitochondrial and cell
volumes, plasma membrane potential and the mitochondrial
membrane potential in permeabilised cells were also measured.
Before cytochrome c release the mitochondrial membrane
potential increased, followed by a decrease in potential
associated with mitochondrial swelling and the release of
cytochrome c and DDP-1, an intermembrane space house
keeping protein. Mitochondrial swelling and cytochrome c
release were both blocked by bongkrekic acid, an inhibitor of
the permeability transition. We conclude that during apoptosis
mitochondria undergo an initial priming phase associated with
hyperpolarisation which leads to an effector phase, during which
mitochondria swell and release cytochrome c. ß 2000 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
A number of pro- and anti-apoptotic members of the Bcl-2
protein family regulate the release of cytochrome c and apop-
tosis inducing factor (AIF) from the mitochondrial intermem-
brane space into the cytosol [1^7]. Cytochrome c then inter-
acts with pro-caspase 9 and Apaf-1 to activate caspase 9 and
thus switch on caspase 3 and commit the cell to apoptosis, in
contrast AIF goes directly to the nucleus where it induces
nuclear condensation [5^10]. There are considerable uncer-
tainties about how cytochrome c and AIF are released from
mitochondria and about the events leading up to their appear-
ance in the cytosol. At least three scenarios have been pro-
posed: the pro-apoptotic proteins Bax and Bak accelerate
opening of the voltage-dependent anion channel (VDAC) in
the outer membrane and thereby speci¢cally release cyto-
chrome c [11,12] ; apoptosis follows induction of the mito-
chondrial permeability transition, caused by formation of a
pore in the inner membrane [13] which leads to matrix swell-
ing, rupture of the outer membrane and release of AIF and
cytochrome c [14^18]; ¢nally, mitochondrial hyperpolarisa-
tion leads to swelling and outer membrane rupture, but with-
out the mitochondrial depolarisation associated with the per-
meability transition [19,20].
The most informative measure of the changes associated
with cytochrome c release is the mitochondrial membrane
potential. However, such measurements in apoptotic cells
have produced con£icting results, with reports of no decrease
in potential until after cytochrome c release [21^25], a de-
crease in membrane potential associated with cytochrome c
release [6,14^17,26], and ¢nally an initial increase in potential
followed by cytochrome c release without loss of membrane
potential [19,20]. These measurements rely on the uptake of
£uorescent dyes, which gives a qualitative indication of the
membrane potential but can be di⁄cult to quantitate and
often fails to detect large changes in potential due to satura-
tion of dye uptake [1,27^29]. Alterations to mitochondrial and
cell volume and plasma membrane potential also contribute to
dye uptake and must be taken into account before a change in
mitochondrial potential is con¢rmed [27,30].
To overcome these di⁄culties we measured mitochondrial
membrane potential changes during apoptosis using the up-
take of the radiolabelled lipophilic cation methyltriphenyl-
phosphonium (TPMP) [27,29^33]. The uptake of TPMP is
easily quantitated and responds to the mitochondrial mem-
brane potential over all values [27,30,33], enabling small
changes in membrane potential to be measured sequentially
at short time intervals during apoptosis. The Jurkat T lym-
phocyte cell line was chosen because it undergoes apoptosis by
cytochrome c release in response to the protein kinase inhib-
itor staurosporine (STS). In parallel we measured the release
into the cytosol of cytochrome c and an intermembrane space
house keeping protein DDP-1, ATP/ADP ratio, mitochon-
drial swelling by stereological analysis of electron micro-
graphs, caspase 3 activation, cell volume and plasma mem-
brane potential. From these measurements we could correlate
and order the events occurring during apoptosis. The mito-
chondrial membrane potential increased within 20 min of STS
addition, followed about 40 min later by a gradual mitochon-
drial depolarisation associated with swelling, outer membrane
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rupture and the release of cytochrome c and DDP-1 into the
cytosol. This second phase of mitochondrial outer membrane
rupture was blocked by bongkrekic acid, an inhibitor of the
mitochondrial permeability transition. We conclude that mi-
tochondria undergo two distinct phases during apoptosis : an
initial priming phase that involves hyperpolarisation, which
leads on to an e¡ector phase involving depolarisation, swell-
ing and cytochrome c release.
2. Materials and methods
2.1. Cell culture and incubations
The Jurkat human T lymphocyte cell line was grown in RPMI 1640
with 10% foetal calf serum (FCS), 100 U/ml penicillin, and 100 Wg/ml
streptomycin at 37‡C in humidi¢ed air/5% CO2. Cells (2.5U106 ml)
were incubated in 1 ml RPMI 1640 supplemented with 25 mM
HEPES^NaOH (pH 7.4) and 1% FCS at 37‡C and apoptosis induced
with 2.5 WM STS. To measure the release of mitochondrial inter
membrane space proteins into the cytosol, cells (5U106) were pelleted
and homogenised in 50 Wl STE [250 mM sucrose, 5 mM Tris^HCl (pH
7.4) and 1 mM EGTA] containing Boehringer Mannheim Complete1
protease inhibitors and the cytosolic fraction isolated by centrifuga-
tion (100 000Ug for 10 min in a Beckman Airfuge).
2.2. Apoptosis assays
To measure caspase 3 activity cells (2.5U106) were pelleted by
centrifugation, and suspended in 100 mM HEPES, 10% sucrose,
5 mM dithiothreitol, 1036% NP-40 and 0.1% CHAPS at pH 7.25
supplemented with 50 WM DEVD-AMC. The release of AMC was
measured in a Perkin-Elmer MPF-3L £uorescence spectrophotometer
(excitation 355 nm, emission 460 nm) at 37‡C, calibrated using an
AMC standard curve. DNA was extracted from cells (2.5U106) using
a Qiagen DNeasy1 tissue kit, and equal amounts separated by elec-
trophoresis on a 2% agarose gel and visualised by ethidium bromide
£uorescence. Annexin V binding was determined by incubating cells
with Annexin V-Fluos (Roche) according to the manufacturer’s in-
structions and Annexin positive cells were quantitated using a FACS-
can £ow cytometer.
2.3. Immunoblotting
Proteins separated on a 15 or 17.5% Tris/Tricine gel, were trans-
ferred to nitrocellulose, incubated with primary antibody followed by
horseradish peroxidase-conjugated secondary antibody and immuno-
reactivity was detected using the Pierce SuperSignal West Pico chem-
iluminescent substrate. Bands were quantitated using a Bio-Rad GS-
670 imaging densitometer. The primary antibodies used were anti-
pigeon cytochrome c monoclonal mouse IgG2b from Pharmingen
and the anti-DDP-1 rabbit anti-serum raised against a GST-human
DDP-1 fusion protein (kindly provided by Dr Carla Koehler, UCLA).
2.4. Measurement of mitochondrial membrane potential
Cells (2.5U106) were incubated at 37‡C in 1 ml RPMI/HEPES/FCS
supplemented with 1 WM TPMP, 100 nCi/ml [3H]TPMP and 500 nM
sodium tetraphenylboron (TPB). The total time of exposure to
TPMP/TPB was always 60 min, consequently for longer incubations
TPMP/TPB were added 60 min before the end of the incubation,
while for shorter incubations TPMP/TPB were preincubated with cells
before addition of STS. The lipophilic anion TPB facilitates rapid
equilibration of TPMP [31,32]. After incubation the cells were pelleted
by centrifugation (10 000Ug for 30 s), 50 Wl supernatant removed, the
cell pellet resuspended in 50 Wl 20% Triton X-100 and the radioactiv-
ity in the pellet and supernatant quantitated using an LKB Wallac
RackBeta liquid scintillation counter with appropriate quench correc-
tions [31,32]. Non-speci¢c TPMP binding to de-energised cells was
determined in a parallel incubation supplemented with 12.5 WM oli-
gomycin, 20 WM carbonyl cyanide-p-(tri£uoromethoxy)phenylhydra-
zone (FCCP), 1 WM myxothiazol, 100 nM valinomycin, and 1 mM
ouabain to eliminate mitochondrial and plasma membrane potentials.
Energisation-dependent TPMP uptake is expressed as an accumula-
tion ratio in units of [(TPMP/mg protein)/(TPMP/Wl supernatant)]
[32]. To measure TPMP accumulation by digitonin-permeabilised
cells, cells were incubated as above, then pelleted and resuspended
in 250 Wl medium [120 mM KCl, 10 mM HEPES^KOH (pH 7.4)
and 1 mM EGTA] supplemented with 1 WM TPMP, 100 nCi/ml
[3H]TPMP, 20 Wg/ml digitonin, 10 mM succinate and 50 WM rotenone
[34]. After 10 min at 37‡C the permeabilised cells were pelleted by
centrifugation (10 000Ug for 30 s), and the pellets and supernatants
processed and assayed for radioactivity as above. Non-speci¢c TPMP-
binding was determined from parallel incubations supplemented with
400 nM FCCP and the energisation-dependent TPMP uptake was
expressed as an accumulation ratio as above.
2.5. Transmission electron microscopy
After incubation cells were pelleted by centrifugation (1000Ug for
2 min) placed in ¢xative (1% glutaraldehyde, 3 mM CaCl2, and 0.1 M
cacodylate pH 7.2 in PBS) for 30 s, and then incubated in fresh
¢xative for 1 h at 37‡C. The cell pellet was washed with 3 mM CaCl2,
0.15 M cacodylate, pH 7.2, warmed to 40‡C and mixed with 2% (w/v)
low melting point agarose in 0.1 M cacodylate (pH 7.2) and concen-
trated by centrifugation (1000Ug for 10 s). The agarose plugs were
post-¢xed in 1% OsO4, 1.5% potassium ferrocyanide and 100 mM
cacodylate bu¡er for 60 min at room temperature, embedded in resin,
and ultra thin sections were obtained for examination in a Philips 410
transmission electron microscope. The fraction of cytosol occupied by
mitochondria was measured stereologically by overlaying 20U25 cm
electron micrographs (19 000U enlargements; 20 randomly selected
for each determination) with a 15 mm square grid and counting
grid points that intersect with either mitochondria or cytosol [32].
2.6. Other procedures
Protein concentrations were determined using the bicinchoninic acid
assay with BSA as a standard [35]. The cellular ATP/ADP ratio was
measured by quenching cell incubations in perchloric acid and assay-
ing neutralised aliquots for ATP and ADP by a luciferase lumino-
meter assay [34]. Plasma membrane potential was measured using
standard intracellular recording techniques [34]. Cells were incubated
as described above and then added to a glass petri dish, causing cells
to stick to the substrate. Intracellular recordings were made with glass
micropipettes ¢lled with 3 M KCl. Pipettes typically had DC resistan-
ces of 40^60 M6. Membrane potentials were monitored with a WP
Instruments (Sarasota, FL, USA) Cyto 721 electrometer ampli¢er,
and the output was displayed using a MacLab system (AD Instru-
ments, Castle Hill, Australia). For recording purposes, cells were
maintained at V24^26‡C and data are means þ S.E.M. of 5^9 deter-
minations on two or three separate cell incubations from cells that
gave stable potential readings, indicating a good seal of the plasma
membrane with the recording electrode. The potentials measured are
the same as those determined for thymocytes from the equilibration of
radiolabelled probes [30], indicating that after electrode insertion the
plasma membrane potential immediately reestablished its normal val-
ue. Cell volume was measured from the exclusion of 14C-inulin rela-
tive to 3H2O [30,32].
3. Results
To determine the time scale of apoptosis, Jurkat cells were
incubated with STS and DNA was extracted at hourly inter-
vals (Fig. 1A). DNA laddering was detected within 3 h and
was not seen in control incubations of up to 6 h (Fig. 1A).
The proportion of Annexin positive cells was unchanged after
incubation with STS for an hour, but increased to V45%
after 2 h incubation and to V70% after 3 h incubation with
STS. Nuclear condensation was also evident in electron mi-
crographs of STS-treated cells after 3 h (data not shown). To
con¢rm that apoptosis was a consequence of cytochrome c
release from mitochondria and subsequent caspase activation
we measured these at 20 min intervals over the 3 h leading up
to DNA laddering (Fig. 1B,C). After 60^120 min increasing
amounts of cytochrome c were detected in the cytoplasm with
most release occurring from 120 to 180 min (Fig. 1B). Caspase
3 activity was negligible for up to 60 min, but from then on
there was a steady increase in activity which peaked after
180 min (Fig. 1C). The activation of caspase 3 correlates
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with cytochrome c release and precedes DNA laddering (Fig.
1). This sequence was con¢rmed by blocking caspase 3 acti-
vation, but not cytochrome c release, by the broad spectrum
caspase inhibitor benzyloxycarbonyl-valinyl-alaninyl-aspartyl-
(O-methyl)-£uoromethylketone (z-VAD-fmk) (data not
shown). Deafness Dystonia Peptide 1 (DDP-1), a component
of the mitochondrial protein import machinery in the inter-
membrane space [36], was also released into the cytosol over
the same time scale as cytochrome c (Fig. 1D).
To investigate the mitochondrial changes that precede and
accompany cytochrome c release we measured the membrane
potential at 20 min intervals during apoptosis from the accu-
mulation of the radioactive lipophilic cation TPMP (Fig. 2A).
The TPMP accumulation ratio increased within 20 min of
STS treatment and remained elevated for about an hour.
After this it steadily declined until there was no energy depen-
dent TPMP accumulation after 3 h. In control cells there was
no change in TPMP accumulation over 3 h. The initial ele-
vation in TPMP accumulation was the same size as that
caused by bongkrekic acid, an inhibitor of mitochondrial
ATP transport. Changes in the cell volume and the plasma
membrane potential a¡ect TPMP accumulation by whole cells
[30]. The cell volume was unchanged when measured 30 min
after addition of STS or bongkrekic acid (control = 0.2 þ 0.06
pl;+STS = 0.16 þ 0.06 pl;+bongkrekic acid = 0.17 þ 0.05 pl).
The plasma membrane potentials of cells measured 20^40
min after addition of STS or bongkrekic acid were also un-
changed (control =338.3 þ 8.4 mV;+STS =340.6 þ 4.1 mV;+
bongkrekic acid =341.0 þ 2.9 mV). Therefore the changes in
TPMP accumulation by whole cells are due to mitochondria
alone.
To determine whether these changes in mitochondrial mem-
brane potential were due to permanent changes in the mito-
chondria themselves we incubated cells with STS, then we
permeabilised the plasma membrane with digitonin and meas-
ured the TPMP accumulation ratio in the presence of a res-
piratory substrate. This procedure enables mitochondrial
function to be analysed directly, without interference from
non-mitochondrial factors, such as ATP-turnover and the
plasma membrane potential [32]. STS treatment did not a¡ect
the TPMP accumulation ratios of permeabilised cells for up to
40 min, after which time the mitochondrial membrane poten-
tial steadily declined, indicating that the decrease in TPMP
accumulation ratio seen after an hour in intact cells corre-
sponds to irreversible disruption of the mitochondria (Fig.
2B). However, the initial hyperpolarisation seen in intact cells
was not found in the permeabilised cells. As the mitochondria
in the permeabilised cells are respiring in the absence of ATP
turnover their membrane potential is at its maximum value, in
contrast to the situation within cells where ATP synthesis
keeps the mitochondrial membrane potential at a sub-maxi-
mal value. Therefore the increase in TPMP accumulation seen
in intact cells is not due to a stable stimulation of the respi-
ratory chain, but is more likely due to an inhibition of ATP
synthesis leading to an increase in the mitochondrial mem-
brane potential.
The cellular ATP/ADP ratio was determined as a further
measure of changes in mitochondrial function during apopto-
sis (Fig. 2C). STS-treated cells maintained their ATP/ADP
ratio for about 40 min, after which time the ratio steadily
Fig. 1. STS-induced apoptosis in Jurkat cells. Cells were incubated
with 2.5 WM STS for the indicated times. A: DNA was extracted
from 2.5U106 cells and separated on a 2% agarose gel and com-
pared with a 100 bp ladder (left lane). B: Cytosolic fractions were
analysed by immunoblotting for cytochrome c. C: caspase 3 activity
was measured as the rate of DEVD-AMC cleavage in extracts from
control (triangles) or STS-treated cells (squares). D: Cytosolic frac-
tions were analysed by immunoblotting for DDP-1. Results are rep-
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declined, in parallel with the decrease in TPMP accumulation
by intact and permeabilised cells.
To determine if the release of cytochrome c and DDP-1
from mitochondria seen in Fig. 1 was due to mitochondrial
swelling and consequent outer membrane rupture, we visual-
ised mitochondria within cells undergoing apoptosis by trans-
mission electron microscopy (Fig. 3). No signi¢cant altera-
tions in mitochondrial morphology were seen after 30 min
of STS treatment (Fig. 3A,B). After 60 min mitochondria
started to swell (Fig. 3C) and at 120 min (Fig. 3D) and par-
ticularly at 180 min (Fig. 3E), large swollen mitochondria
could be seen. In contrast, the mitochondria in control cells
were unchanged after 180 min (Fig. 3F). To quantitate swell-
ing the mitochondrial volume was determined by stereological
analysis of electron micrographs (Fig. 3G). There was no in-
crease in mitochondrial volume within 40 min of STS treat-
ment, but swelling was evident at 60 min and peaked after
120 min (Fig. 3G), while the mitochondrial volume in control
cells did not change (Fig. 3G). The lack of mitochondrial
swelling within 40 min of STS treatment indicates that the
Fig. 3. Mitochondrial swelling during apoptosis. Cells were incu-
bated in the presence or absence of STS, then ¢xed and examined
by transmission electron microscopy. Control incubations were for
0 h (A) or 3 h (F). Incubations with STS were for 30 min (B), 1 h
(C), 2 h (D) or 3 h (E). G: The mitochondrial volume in STS-
treated (¢lled squares) or control cells (open triangles), determined
by stereological analysis of 20 electron micrographs þ S.E.M., for
each time point.
Fig. 2. Mitochondrial changes during apoptosis. Cells were incu-
bated in the presence (¢lled squares) or absence (open triangles) of
2.5 WM STS, or in the presence of 15 WM bongkrekic acid (open
circles). Measurements are expressed as a percentage of control in-
cubations at time zero. A: Mitochondrial membrane potential in in-
tact cells measured as a TPMP accumulation ratio. B: Intact cells
were incubated with STS for the indicated times, then isolated, per-
meabilised with digitonin and their TPMP accumulation ratios de-
termined. C: ATP/ADP ratio in intact cells. The ATP/ADP ratio of
intact cells at time zero was about 10. All data are means þ S.E.M.
of at least three separate experiments.
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early increase in TPMP accumulation by intact cells (Fig. 2A)
was caused by an increase in membrane potential, rather than
mitochondrial swelling.
To correlate the events occurring during apoptosis we plot-
ted the normalised changes in membrane potential, ATP/ADP
ratio, mitochondrial volume, cytochrome c release and casp-
ase activation on a single graph (Fig. 4). This makes clear
that there are two phases in the activation of apoptosis by
mitochondria: a priming phase characterised by mitochon-
drial hyperpolarisation that occurs without swelling, release
of cytochrome c or caspase activation. After about an hour
this leads onto an e¡ector phase during which there is a de-
cline in membrane potential and ATP/ADP ratio associated
with mitochondrial swelling, cytochrome c release and caspase
activation (Fig. 4).
The mitochondrial changes seen during the e¡ector phase of
apoptosis have a number of similarities to induction of the
mitochondrial permeability transition [13]. The permeability
transition occurs following formation of a pore in the inner
membrane that leads to depolarisation, swelling and rupture
of the outer membrane, followed by the release of intermem-
brane space proteins [13,18]. Pre-incubating cells with the per-
meability transition inhibitor bongkrekic acid [16] prior to
addition of STS blocked cytochrome c release, caspase 3 acti-
vation and mitochondrial swelling on addition of STS (data
not shown).
4. Discussion
Jurkat cells treated with the protein kinase inhibitor STS
rapidly underwent apoptosis, with DNA degradation, Annex-
in V binding and nuclear condensation evident within 3 h
(Fig. 1). Caspase activation, following cytochrome c release
into the cytosol, preceded the nuclear changes and was detect-
able after an hour (Fig. 1). Our data enable us to draw con-
clusions about the events that occur in mitochondria in the
hour leading up to cytochrome c release (the priming phase),
and about how mitochondria then release cytochrome c (the
e¡ector phase).
The TPMP accumulation ratio of intact cells increased
within 20 min and remained elevated for up to an hour during
the priming phase (Fig. 2A). It was due to an increase in the
mitochondrial membrane potential itself, as there was no
change in plasma membrane potential, or in cell or mitochon-
drial volume. An increase in activity of the respiratory chain
was not responsible, as the membrane potential of mitochon-
dria in digitonin-permeabilised cells in state 4 was unchanged
over the ¢rst hour (Fig. 2B). This ¢nding of an increase in
membrane potential early in apoptosis is in agreement with
other reports [19,20,37]. Inhibition of mitochondrial ATP
transport by bongkrekic acid increased TPMP accumulation
to the same extent as STS (Fig. 2A) by shifting the cells from
state 3, where ATP synthesis decreases the potential, to state 4
where the absence of ATP synthesis leads to maximal poten-
tial. STS could also do this by inhibiting either ATP synthesis
or transport, but inhibition of transport is the likely cause as
this is known to decrease in cells undergoing apoptosis [20].
The decrease in ATP transport could arise from impeding the
adenine nucleotide carrier in the inner membrane and/or
VDAC in the outer membrane. As both proteins are compo-
nents of the permeability transition pore a link between inhi-
bition of ATP transport and induction of the permeability
transition is suggested.
The release of cytochrome c from the intermembrane space
into the cytosol was associated with mitochondrial swelling
and the release of other intermembrane space proteins (Figs.
1,3 and 4). This suggests that swelling and outer membrane
rupture is the mechanism of release (Fig. 1), and this is sup-
ported by other reports of the release of house keeping inter-
membrane space proteins [24] and mitochondrial swelling [19]
during apoptosis. This swelling correlates with a decline in
membrane potential and ATP/ADP ratio in intact cells, and
also with a decrease in the membrane potential in permeabi-
lised cells (Fig. 2). That cytochrome c release occurs at the
same time as an irreversible decline in mitochondrial function
and is associated with swelling and permeabilisation of the
outer membrane is consistent with induction of the mitochon-
drial permeability transition [18]. Supporting this, the perme-
ability transition inhibitor bongkrekic acid prevented mito-
chondrial swelling and release of cytochrome c.
There was no release of cytochrome c without a decrease in
mitochondrial membrane potential (Fig. 4). How can this be
reconciled with the many reports that cytochrome c release
occurs before a decrease in membrane potential [19,23^25]?
While the decline in membrane potential started after an hour,
by 2 h there was still a substantial potential present, even
though considerable cytochrome c release had occurred (Fig.
4). This residual potential may be su⁄cient to cause substan-
tial uptake of £uorescent dyes into mitochondria that is di⁄-
cult to distinguish from that by fully energised mitochondria
[29]. Alternatively, there is growing evidence for two pathways
of cytochrome c release from mitochondria during apoptosis:
rupture of the outer membrane following swelling, or through
a speci¢c pore in the outer membrane [1,11,12]. In liposomes
and yeast Bax and Bak interact with VDAC to cause selective
cytochrome c release [12]. Addition of recombinant Bax to
isolated mitochondria induced cytochrome c loss without
swelling [11], however others have shown that Bax does in-
duce the permeability transition in isolated mitochondria and
within cells [38,39]. However cleavage of Bid by caspase 8
leads to a Bid fragment that facilitates Bax insertion into
the outer membrane and thereby induces cytochrome c release
independently of the permeability transition [1,40]. In sum-
mary, the pro-apoptotic proteins Bax and Bak interact with
Fig. 4. The priming and e¡ector phases of apoptosis. Changes in
mitochondrial membrane potential (open triangles), ATP/ADP ratio
(open circles), cytochrome c release (closed circles) and caspase ac-
tivity (closed squares) are plotted against time. Data are normalised
to show changes as a percentage of the di¡erence between minimum
and maximum values. The cytochrome c release data were obtained
by scanning densitometry of three immunoblots similar to Fig. 1B.
FEBS 23805 16-6-00
J.L. Scarlett et al./FEBS Letters 475 (2000) 267^272 271
both VDAC and the adenine nucleotide carrier. In some cir-
cumstances this may lead to assembly of the permeability
transition pore, mitochondrial swelling, outer membrane rup-
ture and cytochrome c release. However under di¡erent con-
ditions the interaction between Bax/Bak and VDAC may
form an outer membrane pore selective for cytochrome c,
but it is unclear if this occurs in mammalian cells undergoing
apoptosis, or is an artifact of disruption of VDAC by Bax/
Bak in heterologous and in vitro systems.
In conclusion, we have shown that there are two phases of
mitochondrial activity during STS-induced apoptosis in Jur-
kat cells. An early priming phase associated with an increased
membrane potential, followed by an e¡ector phase associated
with a decline in mitochondrial function, mitochondrial swell-
ing and release of inter membrane space proteins into the
cytosol. An appealing scenario to explain these data is that
during the priming phase the adenine nucleotide carrier,
VDAC, cyclophilin D and other proteins are recruited to
form the permeability transition pore [13]. The depletion of
functional adenine nucleotide carrier and/or VDAC decreases
ATP transport, thus increasing the membrane potential due to
the shift from state 3 to state 4. After 40 min or so, su⁄cient
permeability transition pores have formed to decrease the
membrane potential and initiate mitochondrial swelling and
cytochrome c release. bongkrekic acid and anti-apoptotic pro-
teins such as Bcl-XL may act by decreasing the availability of
the adenine nucleotide carrier and/or VDAC to form perme-
ability transition pores [19].
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